Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. Among authors: arribas jr. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
Berenguer J, González J, Pulido F, Padilla B, Casado JL, Rubio R, Arribas JR; Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis. Berenguer J, et al. Among authors: arribas jr. Clin Infect Dis. 2002 Feb 1;34(3):394-7. doi: 10.1086/338401. Epub 2001 Dec 19. Clin Infect Dis. 2002. PMID: 11753827 Clinical Trial.
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).
Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Del Palacio A, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Arribas JR, et al. AIDS. 2002 Jul 26;16(11):1554-6. doi: 10.1097/00002030-200207260-00014. AIDS. 2002. PMID: 12131195 Clinical Trial.
Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort).
Suárez-Lozano I, Fajardo JM, Garrido M, Roca B, García-Alcalde ML, Geijo P, Selma D, Lozano F, Teira R, Viciana P, Pérez-Cortés S, Domingo P, Menchero A, Galindo MJ, Cosín J, Ribera E, Arribas JR, Lacalle JR. Suárez-Lozano I, et al. Among authors: arribas jr. AIDS. 2002 Dec 6;16(18):2496-9. doi: 10.1097/01.aids.0000042931.55529.82. AIDS. 2002. PMID: 12461432 No abstract available.
Treatment of advanced HIV infection.
Pulido F, Arribas JR. Pulido F, et al. Among authors: arribas jr. J Antimicrob Chemother. 2003 Feb;51(2):225-7. doi: 10.1093/jac/dkg065. J Antimicrob Chemother. 2003. PMID: 12562685 Review. No abstract available.
Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, Arribas JR, Salas A, Laguna F, Sust M, Cañavate C, Alvar J; Spanish HIV-Leishmania Study Group. López-Vélez R, et al. Among authors: arribas jr. J Antimicrob Chemother. 2004 Mar;53(3):540-3. doi: 10.1093/jac/dkh084. Epub 2004 Jan 22. J Antimicrob Chemother. 2004. PMID: 14739148 Clinical Trial.
Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study.
Perez-Elias MJ, Garcia-Arota I, Muñoz V, Santos I, Sanz J, Abraira V, Arribas JR, González J, Moreno A, Dronda F, Antela A, Pumares M, Martí-Belda P, Casado JL, Geijos P, Moreno S; Realvirfen study group. Perez-Elias MJ, et al. Among authors: arribas jr. Antivir Ther. 2003 Dec;8(6):577-84. Antivir Ther. 2003. PMID: 14760891 Clinical Trial.
Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction].
Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E. Berenguer J, et al. Among authors: arribas jr. Enferm Infecc Microbiol Clin. 2004 Mar;22(3):160-76. doi: 10.1016/s0213-005x(04)73057-8. Enferm Infecc Microbiol Clin. 2004. PMID: 14987537 Review. English, Spanish.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. Among authors: arribas jr. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
382 results